Memantine Hcs (Memantine Hydrochloride)

Memantine blocks the NMDA‑type glutamate receptors in a non‑competitive manner, reducing excessive calcium influx that can cause neuronal damage. This neuroprotective action helps slow the progression of cognitive decline associated with Alzheimer’s disease.

The dosage of Memantine Hcs is determined by the prescribing clinician based on the patient’s condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for memantine in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Memantine belongs to the NMDA antagonist class, whereas other approved agents such as cholinesterase inhibitors (donepezil, rivastigmine) act on acetylcholine pathways. Memantine is typically used in moderate to severe stages and may be combined with a cholinesterase inhibitor for additive benefit.

Memantine Hcs should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Do not store in extreme heat or humidity, and keep the product out of reach of children.

Memantine Hcs is taken orally, usually once daily after a meal to improve absorption and reduce gastrointestinal discomfort. The tablet should be swallowed whole with water and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious risks include seizures, severe allergic reactions such as Stevens‑Johnson syndrome, and cardiac arrhythmias. Patients experiencing these symptoms should seek immediate medical attention, and clinicians should monitor high‑risk individuals closely.

Memantine Hcs is contraindicated in patients with known hypersensitivity to memantine or any component of the formulation. Caution is advised for individuals with severe renal impairment, uncontrolled epilepsy, or those taking other NMDA antagonists.